TrialRheumatology (Oxford, England)2018

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Alice B Gottlieb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.